GO:0106026 Gly-tRNA(Ala) deacylase activity: Mechanism, Genes

GO:0106026, Gly-tRNA(Ala) deacylase activity, is a molecular function that catalyzes the hydrolysis of glycyl-tRNA(Ala) to yield free glycine, tRNA(Ala), and a proton. This activity is essential for translational fidelity because it corrects a potentially deleterious error: the mischarging of tRNA(Ala) with glycine by alanyl-tRNA synthetase (AlaRS). Without this proofreading step, glycine would be inserted at alanine codons, producing aberrant proteins. The primary enzyme responsible for this activity is D-aminoacyl-tRNA deacylase (DTD), which acts as a trans-editing factor to hydrolyze the mischarged tRNA. DTD was initially characterized for its role in clearing D-aminoacyl-tRNAs, but subsequent studies revealed its broader function in eliminating Gly-tRNA(Ala). This dual substrate specificity highlights the evolutionary pressure to maintain a robust defense against mistranslation. For researchers, GO:0106026 represents a focal point for understanding how cells balance amino acid supply, tRNA charging, and protein synthesis quality control. Defects in this activity have been linked to proteotoxic stress and may contribute to disease states where mistranslation plays a role. Thus, investigating Gly-tRNA(Ala) deacylase activity offers insights into fundamental translation mechanisms and potential therapeutic targets.

Gly-tRNA(Ala) deacylase activity (GO:0106026) is defined as the catalysis of the reaction: glycyl-tRNA(Ala) + H2O = tRNA(Ala) + glycine + H+. In other words, it is an enzymatic activity that removes the amino acid glycine from a tRNA molecule that is normally charged with alanine, thereby preventing the misincorporation of glycine into proteins at alanine codons.

Gly-tRNA(Ala) deacylase activity is fundamentally important because it safeguards the accuracy of protein synthesis. Errors in aminoacyl-tRNA selection can lead to proteome-wide mistranslation, which is toxic and has been implicated in aging and disease. By hydrolyzing Gly-tRNA(Ala), DTD ensures that glycine is not mistakenly incorporated at alanine codons, preserving protein structure and function. This activity also represents a paradigm for understanding how cells use trans-editing factors to enhance translational fidelity beyond the inherent proofreading of aminoacyl-tRNA synthetases. Moreover, the dual role of DTD in chiral proofreading and glycine deacylation underscores the interconnected nature of quality-control pathways. Studying this activity can reveal vulnerabilities in pathogens that rely on DTD for survival, suggesting potential antibiotic targets. In higher organisms, defects in this pathway may contribute to neurodegeneration and other diseases linked to protein misfolding.

The following genes and proteins are central to Gly-tRNA(Ala) deacylase activity and its associated quality-control pathways.

The activity of Gly-tRNA(Ala) deacylase is primarily regulated at the level of enzyme expression and substrate availability. In bacteria, DTD expression is constitutive but can be induced under conditions of amino acid starvation or mistranslation stress. The activity is also influenced by the cellular levels of glycine and alanine, as high glycine concentrations can promote mischarging of tRNA(Ala) by AlaRS, thereby increasing the substrate for DTD. Additionally, post-translational modifications of DTD may modulate its activity, although specific modifications remain to be fully characterized. The discriminator base A73 in tRNA(Ala) acts as a cis-acting element that determines whether DTD can hydrolyze the mischarged tRNA. In eukaryotes, DTD1 is localized to the cytoplasm and its activity may be coordinated with the translational machinery. Overall, regulation ensures that DTD is available when needed to maintain translational fidelity.

Defects in translational quality control, including Gly-tRNA(Ala) deacylase activity, have been linked to neurodegenerative diseases. Mutations in alanyl-tRNA synthetase (AARS1) that impair editing can cause Charcot-Marie-Tooth disease and other neuropathies due to proteotoxic stress from glycine misincorporation. DTD provides a backup editing mechanism, and its dysfunction may exacerbate such conditions. Understanding this pathway could lead to therapeutic strategies that enhance deacylation activity.

Cancer cells often exhibit increased translational rates and are sensitive to mistranslation. Loss of DTD activity could lead to proteome instability, which may promote tumorigenesis or, conversely, create vulnerabilities that can be exploited therapeutically. Studies in model organisms suggest that DTD deficiency leads to growth defects and stress responses that overlap with cancer-associated pathways.

Bacterial DTD is essential for survival under conditions that promote mistranslation, making it a potential target for new antibiotics. Inhibitors of DTD could selectively kill pathogens by overwhelming them with mistranslated proteins. This is particularly relevant for drug-resistant bacteria where traditional antibiotics fail.

In vitro deacylation assays using purified DTD and radiolabeled glycyl-tRNA(Ala) are the gold standard for measuring Gly-tRNA(Ala) deacylase activity. These assays monitor the release of free glycine over time and can be used to determine kinetic parameters and substrate specificity. They are essential for validating enzyme function and testing inhibitors.

Ribo-seq allows genome-wide detection of mistranslation events by mapping ribosome footprints. In DTD-deficient cells, increased glycine misincorporation at alanine codons can be observed as altered codon occupancy. This method provides a quantitative readout of translational fidelity.

Mass spectrometry-based proteomics can identify proteins containing glycine substitutions at alanine positions. This approach is powerful for assessing the global impact of DTD loss on proteome integrity. It can also detect changes in protein aggregation and stability.

CRISPR-Cas9 knockout of DTD1 or RNAi knockdown are used to study the cellular consequences of losing Gly-tRNA(Ala) deacylase activity. These models reveal growth defects, stress responses, and changes in translation. They are foundational for linking the activity to phenotypes.

Researchers studying Gly-tRNA(Ala) deacylase activity-related genes often need to determine whether a candidate gene is causally involved in translational fidelity, stress responses, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models, enabling rigorous functional studies of DTD1, AARS1, and related genes.

Gly-tRNA(Ala) deacylase activity (GO:0106026) is a vital quality-control mechanism that protects cells from the deleterious effects of glycine misincorporation during protein synthesis. The enzyme DTD, encoded by DTD1, hydrolyzes glycyl-tRNA(Ala) to maintain translational fidelity, and its loss leads to proteotoxic stress and growth defects. Understanding this activity has implications for neurodegenerative diseases, cancer, and infectious diseases, and it offers a target for therapeutic intervention. Researchers can leverage CRISPR-based models and advanced omics methods to further dissect the molecular details and physiological roles of this essential activity.